Advertisement

Managing the Complications of Diabetes

  • Santosh Shankarnarayan
Chapter

Abstract

Chronic hyperglycemia is associated with many serious complications (eg, heart disease, stroke, end-stage renal disease [ESRD], nerve disease, dental disease, blindness, amputations) and premature mortality. The results from the Diabetes Control and Complications Trial (DCCT) and the UK Prospective Diabetes Study (UKPDS) convincingly demonstrate the importance of good glycemic control to prevent microvascular complications of diabetes.

Keywords

Diabetic Nephropathy Diabetic Retinopathy Macular Edema Diabetic Neuropathy Autonomic Neuropathy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Roglic G, Unwin N, Bennett PH. The burden of mortality attributable to diabetes: realistic estimates for the year 2000. Diabetes Care. 2005;28:2130–2135.Google Scholar
  2. 2.
    Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med.1993;329:977.Google Scholar
  3. 3.
    UK Prospective Diabetes Study Group (UKPDS 33). Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet.1998;352:837–853.Google Scholar
  4. 4.
    Setter SM, Campbell RK, Cahoon C. Biochemial pathways of microvascular complication in diabetes mellitus. Ann Pharmacother. 2003;37:1858–1866.Google Scholar
  5. 5.
    Kuroki T, Isshiki K, King G. Oxidative stress: the lead or supporting actor in the pathogenesis of diabetic complications. J Am Soc Nephrol. 2003;14:S216–220.Google Scholar
  6. 6.
    Harris MI, Klein R, Welborn TA. Onset of NIDDM occurs at least 4–7 years before clinical diagnosis. Diabetes Care. 1992;15:815–819.Google Scholar
  7. 7.
    Molitch ME, DeFronzo RA, Franz MJ, et al. Diabetic nephropathy. Diabetes Care. 2003;26:S94–8.Google Scholar
  8. 8.
    Molitch ME, DeFronzo RA, Franz MJ, et al. Nephropathy in diabetes. Diabetes Care. 2004;27:S79–83.Google Scholar
  9. 9.
    Mogensen CE. Microalbuminuria in prediction and prevention of diabetic nephropathy in insulin-dependent diabetes mellitus patients. Diabetes Complics. 1995;9:337–349.Google Scholar
  10. 10.
    Diabetes Control and Complications (DCCT) Research Group. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Intl. 1995; 47:1703.Google Scholar
  11. 11.
    Bending JJ, Viberti GC, WatkinsPJ, Keen H. Intermittent clinical proteinuria and renal function in diabetes: evolution and effect of glycemic control. Br Med J. 1986;292:83.Google Scholar
  12. 12.
    Hansen HP, Tauber-Lassen E, Jensen BR, Parving HH. Effect of dietary protein restriction on prognosis in patients with diabetic nephropathy. Kidney Int. 2002;6:220–228.Google Scholar
  13. 13.
    Breyer JA. Diabetic nephropathy in insulin-dependent patients. Am J Kidney Dis. 1992;20:533.Google Scholar
  14. 14.
    Vora JP, Ibrahim HA, Bakris GL. Responding to the challenge of diabetic nephropathy: the historic evolution of detection, prevention and management. J Hum Hypertens. 2000;14:667–685.Google Scholar
  15. 15.
    Adler AL, Stevens RJ, Manley SE et al. Development and progression of nephropathy in type 2 diabetes. Kidney Intl. 2003;63:225–232.Google Scholar
  16. 16.
    Parving HH, Hommel E. Prognosis in diabetic nephropathy. BMJ. 1989;299:230–233.Google Scholar
  17. 17.
    Bunce C, Wormald R. Causes of blind certifications in England and Wales April 1999 – March 2000. Eye. 2008;905–911.Google Scholar
  18. 18.
    Keenan HA, Costacou T, Sun JK, et al. Clinical factors associated with resistance to microvascular complications in diabetic patients of extreme disease duration: the 50-year medalist study. Diabetes Care. 2007;30:1995–1997.Google Scholar
  19. 19.
    Fong DS, Aiello LP, Ferris FL 3rd, Klein R. Diabetic retinopathy. Diabetes Care. 2004;27:2540–2553.Google Scholar
  20. 20.
    Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813–820.Google Scholar
  21. 21.
    Shams N, Lanchulev T. Role of vascular endothelial growth factor in ocular angiogenesis. Ophthalmol Clin Nth Am. 2006;19:335–344.Google Scholar
  22. 22.
    Sunder RM, Robert H, Skyler J. Atlas of Clinical Endocrinology. Volume 2. London: Current Medicine Group; 1999.Google Scholar
  23. 23.
    Watkins PJ. Retinopathy. BMJ. 2003;326:924–926.Google Scholar
  24. 24.
    Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383–393.Google Scholar
  25. 25.
    Scott R, Best J, Forder P, et al; for the FIELD Study Investigators. Fenofibrate intervention and event lowering in diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]. Cardiovasc Diabetol. 2005;4:13.Google Scholar
  26. 26.
    Ryan EH, Han DP, Ramsay RC. Diabetic macula edema associated with glitazone use. Retina. 2006;26:562–570.Google Scholar
  27. 27.
    Fong DS, Contreras R. Glitazone use associated with diabetic macular edema. Am J Ophthalmol. 2009;147:583–586.Google Scholar
  28. 28.
    Diabetes Control and Complications Trial Research Group. Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Ophthalmology. 1995;102:647.Google Scholar
  29. 29.
    Early Treatment Diabetic Retinopathy Study Research Group (ETDRS). Early photocoagulation for diabetic retinopathy. Ophthalmology. 1994;98:766–785.Google Scholar
  30. 30.
    Blumenkranz MD, Yellachich MS, Andersen D. New instrument: semiautomated patterned scanning laser for retinal photocoagulation. Retina. 2006;26:370–376.Google Scholar
  31. 31.
    Al-Hussainy S, Dodson PM, Gibson JM. Pain response and follow- up of patients undergoing panretinal laser photocoagulation with reduced exposure times. Eye. 2008;26:370–376.Google Scholar
  32. 32.
    Kunisaki M, Bursell SE, Clermont AC, et al. Vitamin E prevents diabetes-induced abnormal retinal blood flow via the diacylglycerol-protein kinase C pathway. Am J Physiol. 1995;269:e239–e246.Google Scholar
  33. 33.
    PKC-DRS2 Group. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology. 2006;113:2221–2230.Google Scholar
  34. 34.
    Ewing DJ. Autonomic neuropathy: its diagnosis and prognosis. Clin Endocrinol Metab. 1986;15:855–888.Google Scholar
  35. 35.
    Boulton A. Management of diabetic peripheral neuropathy. Clinical Diabetes. 2005;23:9–15.Google Scholar
  36. 36.
    Vinik A. Neuropathy: new concepts in evaluation and treatment. South Med J. 2002;95:21–23.Google Scholar
  37. 37.
    Duby JJ, Campbell RK. Diabetic neuropathy: an intensive review. Am J Health-Syst Pharm. 2004;61:160–176.Google Scholar
  38. 38.
    Wong MC, Chung JWY, Wong TKS. Effects of treatments for symptoms of painful diabetic neuropathy: systematic review. BMJ. 2007;335:387.Google Scholar
  39. 39.
    Grief CJ, Conn DK, Reekam RV. The treatment of chronic pain with antidepressants in older adults. J Geriatric Care. 2002;1:255–263.Google Scholar
  40. 40.
    Spallone V, Lacerenza M, Rossi A, Sicuteri R, Marchettini P. Painful diabetic neuropathy: approach to diagnosis and management. Clin J Pain. 2011; [Epub ahead of print].Google Scholar
  41. 41.
    Gimbel JS, Richards P, Portenoy RK. Controlled-release oxycodone for pain in diabetic neuropathy: A randomized controlled trial. Neurology. 2003;60:927–934.Google Scholar
  42. 42.
    Harati Y, Gooch C, Swenson M. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology. 1998;50:1842–1846.Google Scholar
  43. 43.
    Maitra A, Abbas AK. The endocrine system. In: Kumar V, Abbas AK, Fasuto N, eds. Pathologic Basis of Disease. London: Elsevier; 2005:1155–1205.Google Scholar
  44. 44.
    Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:260–272.Google Scholar
  45. 45.
    National Institute for Health and Clinical Excellence. Type 2 diabetes. NICE clinical guidelines 87; 2009. www.nice.org.uk/CG87. Accessed September 5, 2012.
  46. 46.
    National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA. 2003;289:2560–2571.Google Scholar
  47. 47.
    Colhoun HM, Betteridge DJ, Durrington PN, et al; for the CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364:685–696.Google Scholar
  48. 48.
    Collins R, Armitage J, Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361:2005–2016.Google Scholar
  49. 49.
    Janghorbani M, Hu FB, Willett WC, et al. Prospective study of type 1 and type 2 diabetes and risk of stroke subtypes. Diabetes Care. 2007;30:1730–1735.Google Scholar
  50. 50.
    Laing SP, Swerdlow AJ, Carpenter LM, et al. Mortality from cerebrovascular disease in a cohort of 23,000 patients with insulin-treated diabetes. Stroke. 2003;34:418–421.Google Scholar
  51. 51.
    Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002;287:2570–2581.Google Scholar
  52. 52.
    Chinese Acute Stroke Trial Collaborative Group. Randomized placebo-controlled trial of early aspirin use in 20,000 patients with acute ischemic stroke. Lancet. 1997;349:1641.Google Scholar
  53. 53.
    Multicenter Acute Stroke Trial—Italy (MAST-I) Group. Randomized controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischemic stroke. Lancet. 1995;346:509.Google Scholar
  54. 54.
    Murabito JM, D’Agostino RB, Silbershatz H. Intermittent claudication. A risk profile from The Framingham Heart Study. Circulation. 1997;96:44–49.Google Scholar
  55. 55.
    Creager MA, Libby P. Peripheral artery disease. In: Braunwald E, Zipes DP, Libby P, eds. Heart Disease: A Textbook of Cardiovascular Medicine. Philadelphia: WB Saunders Company; 2001.Google Scholar
  56. 56.
    Murphy TP, Cutlip DE, Regensteiner JG, et al. Supervised exercise versus primary stenting for claudication resulting from aortoillac peripheral artery disease. Circulation. 2012;125:130–139.Google Scholar
  57. 57.
    International working group on the diabetic foot. Practical and specific guidelines. IDF website. www.iwgdf.org/index.php. Accessed September 5, 2012.
  58. 58.
    National Institute for Health and Clinical Excellence. NICE clinical guideline CG10type 2 diabetes footcare. www.nice.org.uk/CG10. Accessed September 5, 2012.
  59. 59.
    Heckman, J D, Agarwal, A, Schenck, RC . Current Orthopedic Diagnosis and Treatment. London: Springer; 1999.Google Scholar
  60. 60.
    ACCORD Study Group. Long-term effects of glucose lowering on cardiovascular outcomes. N Engl J Med. 2001;364:818–828.Google Scholar
  61. 61.
    Zoungas S, Chalmers J, Ninoyama T, et al. Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. Diabetologia. 2012;55:636–643.Google Scholar

Copyright information

© Springer Healthcare 2012

Authors and Affiliations

  • Santosh Shankarnarayan
    • 1
  1. 1.Royal Liverpool University HospitalLiverpoolUK

Personalised recommendations